Search

Displaying results 61 to 70 of 87.

Research Group

Biological Barriers and Drug Delivery

While considering the confusing flood of drugs in the pharmacies it is hard to believe in a lack of medication. But there are still many infectious diseases and also cancer that cannot be treated sufficiently. During a medical treatment it is essential that the drug arrives at the envisaged body region. Read more about the research of the department “Biological Barriers and Drug Delivery” on techniques for the correct distribution of novel drugs. This group is located at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) .

Research Group

Chemical Biology of Carbohydrates

Carbohydrates and glycoconjugates belong to the three major classes of biopolymers. Complex carbohydrates play important roles in biological recognition processes that are represented by the presence of dense glycoconjugate layers on cells known as the glycocalyx. Despite their importance, the study of carbohydrates suffers from limited methods for their synthesis and analysis contrary to nucleic acids or proteins. This group is located at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS).

Research Group

Antiviral and Antivirulence Drugs

Work in the Empting lab focuses on tackling innovative and difficult-to-address anti-infective targets such as bacterial virulence regulatory systems as well as un(der)explored anti-herpesviral persitance mediators. By this, we aspire to circumvent common resistance mechanisms and to refill the dried out development pipeline. This group is located at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)

Research Group

Compound Profiling and Screening

The World Health Organization (WHO) considers the spread of microorganisms which are resistant to the most common antibiotics an increasing threat to the well-being of the world population. Not only is the number of patients increasing whose infectious disease can no longer be treated, but also in some circumstances patients with other severe diseases will not be treated if the therapy is accompanied with suppression of the immune system and thus, an increased risk of infection. Thus, new active agents for the treatment of infectious diseases are urgently needed, as well as the responsible use of existing antibiotics. Prerequisites for the discovery of new drugs are relevant biological screening assays together with compound libraries of broad chemical diversity. We perform primary screens, based either on own protocols or on protocols developed by cooperation partners and transferred to our infrastructure. In cooperation with partners we also perform secondary assays to optimize first primary hits.

Research Group

Computational Biology for Individualised Medicine

Infections are among the biggest threats to health and the most significant causes of death worldwide. Our aim is to reveal the host genetic risk factors and their downstream molecular pathways, which are crucial to make progress in understanding and treating infectious diseases in an individualised manner as well as to improve the identification of patients at risk. The department is part of the developing CiiM and currently housed at the TWINCORE in Hannover.

Research Group

Experimental Immunology

Immune cell populations are characterized by a high degree of heterogeneity to enable efficient and specialized responses to the diverse set of pathogens. This is particularly true for cells of the adaptive immune system, but also innate immune cell populations are heterogeneous and can adapt to different environmental conditions. Adaptation of immune cells is often associated with epigenetic alterations that lead to the fixation of gene expression patterns, finally resulting in cells with highly specialized fates, phenotypes and functional properties.

Research Group

Evolutionary Community Ecology

Humans are increasingly part of these interaction networks and pathogen transmission from animals to humans is occurring at increasing rates. Indeed, emerging zoonotic disease are an increasing threat to human health and most of these diseases have their origins in wildlife. Microorganisms and their associated diseases also influence animal populations’ persistence and conservation, with some spilling over to animals from humans as well. The research group ‘evolutionary community ecology’ explores how the changing composition of animal communities has cascading impacts on their microbial communities, diseases, and rates of transmission, including to humans. The department is located at the Helmholtz Institute for One Health .

Research Group

Pathogen Evolution

Ecological interactions that underpin human life are highly dynamic, and changes in complex ecosystems can have far-reaching consequences on human health. Therefore, One Health also has a very strong evolutionary component. Over the last decades, evolutionary biology concepts have provided a major contribution towards unveiling the short- and long-term dynamics of pathogen emergence and spread. The importance of evolutionary approaches has become particularly evident during the COVID-19 pandemic. Both the initial emergence event and the later spread and evolution of SARS-CoV-2 have been investigated using evolutionary genomics – with the rise of variants of concern (VOC) being pointed out in the first place by observational data and inferential statistics. The Department of Pathogen Evolution studies both current and historical samples and uses them to make targeted predictions about the potential spread of important pathogens, thus providing important contributions to public health. The department is located at the Helmholtz Institute for One Health .

Research Group

Biosafety Level 3 Laboratory

Biological agents of risk group 3 (RG3) pose a constant global as well as national challenge because they cause severe illnesses in humans against which there are usually no effective preventive or treatment measures. Since these pathogens can only be handled in special biosafety level 3 (BSL3) laboratories, the modern BSL3 laboratories at the HZI provide a technology platform that is indispensable in today's infection research - only in this way can our scientists develop new therapies, prevention measures or diagnostic procedures against these pathogens.

Research Group

Clinical Bioinformatics

The Department “Clinical Bioinformatics” is concerned with analyzing molecular information using computer-based methods such as machine learning, artificial intelligence, or other algorithms. Its focus lies on spatially and temporally resolved processes to help understand how bacteria, as producers of natural products, interact with humans and can trigger or even protect against disease. This department is located at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) .